Analysis of treatment effectiveness in longitudinal observational data

Journal of Biopharmaceutical Statistics

Volumn 17, Issue 5, 2007, Pages 809-826

  Faries, Douglas ^a   Ascher Svanum, Haya ^a   Belger, Mark ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Casual inference; Marginal structural models; Naturalistic; Time varying confounders

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL METHOD; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 34548823822     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400701513967     Document Type: Article

References (33)

1. Bang, H., Robins, J. M. (2005). Doubly robust estimation in missing data and causal inference models. Biometrics 61:692-972.
2. Benson, K., Hartz, A. J. (2000). A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med. 342:1878-1886.
3. Bodnar, L. M., Davidian, M., Siega-Rizt, A. M., Tsiastis, A. A. (2004). Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. Am. J. Epi. 159(10):926-934,
4. Branson, M., Whitehead, J. (2002). Estimating a treatment effect in survival studies in which patients switch treatment. Stat. Med. 21:2449-2463.
5. Cole, S. R., Hernán, M. A., Robins, J. M., Anastos, K., Chmiel, J., Detels, R., Ervin, C., Feldman, J., Greenblatt, R., Kingsley, L., Lai, S., Young, M., Cohen, M., Munoz, A. (2003). Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am. J. Epi. 158(7):687-694.
6. Cole, S. R., Hernán, M. A., Margolick, J. B., Cohen, M. H., Robins, J. M. (2005). Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 count. Am. J. Epi. 162(5):471-478.
7. Concato, J., Shah, N., Horwitz, R. I. (2000). Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342:1887-1892.
8. Gianfrancesco, F., Wang, R. H., Mahmoud, R., White, R. (2002). Methods for claim-based pharmacoeconomic studies in psychosis. Pharmacoecon 20(8):499-511.
9. Grimes, D. A., Schultz, K. F. (2002). Bias and causal associations in observational research. Lancet 359:248-252.
10. Haro, J. M., Kontodima, S., Negrin, M. A., Ratcliffe, M., Suarez, D., Windmeijer, F. (2006). Methodological aspects in the assessment of treatment effects in observational health outcome studies. Appl. Health Econ Health Policy 5(1):11-25.
11. Hernán, M. S., Brumback, B., Robins, J. M. (2000). Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11(5):561-570.
12. Hernán, M. A., Brumback, B. A., Robins, J. M. (2002). Estimating the casual effect of zidovudine on CD4 count with a marginal model for repeated measures. Stat. Med. 21:1689-1709.
13. Hernán, M. A., Hernandez-Diaz, S., Robins, J. M. (2004). A structural approach to selection bias. Epidemiology 15(5):615-625.
14. Hernán, M. A., Robins J. M., Garcia Rodrigues, L. A. (2005a). Comment on: Prentice, R. L., Pettinger, M., Anderson, G. L. Statistical issues arising in the women's health initiative. Biometrics 61:899-941.
15. Hernán, M. A., Cole, S. R., Margolick, J., Cohen, M., Robins, J. M. (2005b). Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepi and Drug Safety 14(7):477-491.
16. Ko, H., Hogan, J. W., Mayer, K. H. (2003). Estimating causal treatment effects from longitudinal HIV natural history studies using marginal structural models. Biometrics 59:152-162.
17. Leon, A. C., Hedeker, D, (2005). A mixed-effects quintile-stratified propensity adjustment for effectiveness analyses of ordered categorical doses. Stat. Med. 24:647-658.
18. Leon, A. C., Hedeker, D., Teres, J. (2007). Bias reduction in effectiveness analyses of longitudinal ordinal doses with a mixed-effects propensity adjustment. Stat. Med. 26:110-123.
19. Lipkovich, I., Mallinckrodt, C., Faries, D. (2006). Exploring dose response in flexible dose trials using marginal structural models. 2006 Proceedings of the American Statistical Association, Statistical computing section [CD-ROM]. Alexandria, VA: American Statistical Association (in press).
20. Mallinckrodt, C. H., Sanger, T., Dube, S., DeBrota, D., Molenberghs, G., Carroll, R., Potter, W. Z., Tollefson, G. D. (2003). Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol. Psych. 53:754-760.
21. Revicki, D. A., Frank, L. (1999). Pharmacoeconomic evaluation in the real world. Pharmacoecon 15(5):423-434.
22. Robins, J. M. (1999). Marginal structural models versus structural nested models as tools for casual inference. In: Halloran, E., Berry, D., eds. Statistical Models in Epidimology: The Environment and Clinical Trials. New York: Springer-Verlag, pp. 95-134.
23. Robins, J. M., Greenland, S. (1986). The role of model selection in causal inference from non experimental data. Am. J. Epi. 123(3):392-402.
24. Robins, J. M., Hernan, M. A., Brumback, B. (2000). Marginal structural models and causal inference in epidemiology. Epidemiology 11:550-560.
25. Rosenbaum, P. R., Rubin, D. B. (1984). Reducing bias in observational studies using subclassification on the propensity score. JASA 79(387):516-524.
26. SAS Institute Inc. (1999). SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute Inc. Shao, J., Chang, M., Chow, S. C. (2005). Statistical inference for cancer trials with treatment switching. Stat. Med. 24:1783-1790.
27. Sterne, J. A. C., Hernán, M. A., Ledergerber, B., Tilling, K., Weber, R., Sendi, P., Rickenbach, M., Robins, J. M., Egger, M., and the Swiss HIV Cohor Study (2005). Long term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366:378-384.
28. Tager, I. D., Haight, G., Sternfield, B., Yu, Z., van der Laan, M. (2004). Effects of physical activity and body composition on functional limitation in the elderly: application of the marginal structural model. Epidemiology 15(4):479-493.
29. Tunis, S. L., Kinon, B. J., Faries, D. E., Ascher-Svanum, H., Nyhuis, A. W., Aquila, R. (2006). Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, one-year trial. Val. Health 9(2):77-89.
30. Verbeke, G., Molenberghs, G. (2000). Linear Mixed Models for Longitudinal Data. New York: Springer-Verlag Inc.
31. Yamaguchi, T., Ohashi, Y. (2004a). Adjusting for differential proportions of second-line treatment in cancer trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effects. Stat. Med. 23:1991-2003.
32. Yamaguchi, T., Ohashi, Y. (2004b). Adjusting for differential proportions of second-line treatment in cancer trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancer. Stat. Med. 23:2005-2022.
33. Windmeijer, F., Kontodima, S., Knapp, M., Brown, J., Haro, J. M. (2006). A methodological approach for assessing the cost-effectiveness of treatments using longitudinal observational data: the SOHO study. International J. Technology Assessment in Health Care 22:440-468.